Appendix D

## NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE

Single Technology Appraisal (STA)

## Tenofovir disoproxil fumarate for the treatment of hepatitis B

## Response to consultee and commentator comments on the provisional matrix of consultees and commentators (pre-referral)

Version of matrix of consultees and commentators reviewed:									
Provisional matrix of consultees and commentators sent for consultation									
Summary of comments, action taken, and justification of action:									
	Proposal:	Proposal made by:		Action taken: Removed/Added/Not included/Noted	Justification:				

National Institute for Health and Clinical Excellence

Response to comments on the provisional matrix of consultees and commentators (pre-referral) for the appraisal of tenofovir disoproxil fumarate for the treatment of hepatitis B

Issue date: August 2008

1.	The HepC Trust BVHG (British Viral Hepatitis group) should be considered as consultee organisations	Gilead Sciences	Not added	This organisation's interests are not closely related to the appraisal topic and as per our inclusion criteria and equalities commitments. Therefore The HepC Trust has not been added to the matrix. This organisation's interests are closely related to the appraisal topic and as per our inclusion criteria and equalities commitments. Therefore BVHG (British Viral Hepatitis group) have been added to the matrix
2.	Foundation for Liver Research is not included in the list, although I am responding on its behalf	The Foundation for Liver Research	Added	This organisation is currently listed on the matrix under the title of 'Relevant Research Groups'

National Institute for Health and Clinical Excellence

Response to comments on the provisional matrix of consultees and commentators (pre-referral) for the appraisal of tenofovir disoproxil fumarate for the treatment of hepatitis B

Issue date: August 2008